Search

Meet Shai Izraeli, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently the EHA Treasurer, a member of the Executive Board, and the incoming Chair of the Research Committee.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

EHA-Balkan Hematology Day 2024

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 5th edition of the EHA-Balkan Hematology Day.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Chairs and Members

The EHA SWG commenced in 2020, but initial work was delayed due to the COVID-19 pandemic. We therefore started in 2021, in preparation for a (successful) SWG meeting in 2022.

Read more

Wiley and European Hematology Association Announce Partnership

Wiley will publish HemaSphere beginning January 2024

Hoboken, NJ, (USA) and The Hague (Netherlands) – Wiley, one of the world’s largest publishers and a global leader in research and education, today announced that it will publish the open access journal HemaSphere on…

Read more